Defence Therapeutics (TSE:DTC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Defence Therapeutics has appointed Dr. Maxime Parisotto as its new Chief Scientific Officer and Director of Science and Business Development, aiming to leverage his extensive experience in drug development and oncology to enhance shareholder value. The company also granted Dr. Parisotto 100,000 incentive stock options, highlighting its commitment to driving growth through strategic leadership.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Chipotle Mexican Grill, Inc. (NYSE:CMG)
- 3 Penny Stocks to Watch Now, 11/26/24
- Rivian Gets Conditional DOE Loan of $6.6B for Georgia Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
